Skye Bioscience, Inc. (SKYE) NASDAQ
0.82
+0.0923(+12.77%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
0.82
+0.0923(+12.77%)
Currency In USD
Address
11250 El Camino Real
San Diego, CA 92130
United States of America (the)
Phone
858 410 0266
Website
Sector
Healthcare
Industry
Biotechnology
Employees
16
First IPO Date
November 26, 2014
| Name | Title | Pay | Year Born |
| Punit S. Dhillon | President, Chief Executive Officer, Secretary & Director | 714,096 | 1980 |
| Tu Diep | Chief Operating Officer | 475,512 | 1981 |
| Kaitlyn Melanie Arsenault | Chief Financial Officer | 503,361 | 1987 |
| Christopher G. Twitty | Chief Scientific Officer | 0 | 1972 |
| Puneet S. Arora | Chief Medical Officer | 0 | 1972 |
| Brennen Brodersen | General Counsel | 0 | N/A |
Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100, which is in Phase I trials for the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 that is in preclinical trials to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. was founded in 2012 and is headquartered in San Diego, California.